MAP2K7 and central nervous system cancer: Interestingly, although mutations in Ras are not found in gliomas, overexpression and/or gain-of-function mutations in several growth factor receptors increase Ras activity [2]–[4], activating downstream effectors like Raf/MEK/ERK and PI3K/AKT pathways [5].